Current and future treatments for Alzheimer's disease.
TLDR
Current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials are discussed.Abstract:
Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as ‘disease-modifying’ drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulati...read more
Citations
More filters
Journal ArticleDOI
Neuroinflammation, Microglia, and Cell-Association during Prion Disease
James A. Carroll,Bruce Chesebro +1 more
TL;DR: Studies indicate that reduction of the microglial population accelerates disease and increases PrPSc burden in the CNS, and microglia are unlikely to be a foci of prion propagation in the brain, as neurons and astrocytes are known to be involved in prion replication and spread.
Journal ArticleDOI
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.
Mantosh Kumar Satapathy,Ting-Lin Yen,Jing-Shiun Jan,Ruei-Dun Tang,Jia-Yi Wang,Rajeev Taliyan,Chih-Hao Yang +6 more
TL;DR: In this paper, solid lipid nanoparticles (SLNs) have been used as a putative drug carrier system that can deliver the active therapeutics (drugloaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way.
Journal ArticleDOI
Copper Toxicity Links to Pathogenesis of Alzheimer's Disease and Therapeutics Approaches.
TL;DR: A better understanding of Cu ions’ current status in several AD features is presented, and a short review of the modern therapeutic approach in chelation therapy, with the main focus on Cu ions is discussed.
Journal ArticleDOI
Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition
Jong-Chan Park,Sun Ho Han,Hyun Jin Cho,Min Soo Byun,Dahyun Yi,Young Min Choe,Seokjo Kang,Eun Sun Jung,Su Jin Won,Eun-Hye Kim,Yu Kyeong Kim,Dong Young Lee,Dong Young Lee,Inhee Mook-Jung +13 more
TL;DR: MPP-Aβ might be one of the potential blood biomarkers for the prediction of PiB-PET positivity in the brain, and the integrated multivariable logistic regression model proposes a new standard for the Prediction of cerebral amyloid deposition.
Journal ArticleDOI
Neuroprotective Natural Products for Alzheimer's Disease.
TL;DR: In this article, a review of possible neuroprotective mechanisms from natural products that may be beneficial in Alzheimer's disease treatment and the natural product mixtures or extracts from different sources that have demonstrated neuro-protective activity in preclinical and/or clinical studies is presented.
References
More filters
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal ArticleDOI
The Cholinergic Hypothesis of Geriatric Memory Dysfunction
Raymond T. Bartus,Raymond T. Bartus,Reginald L. Dean,Bernard Beer,Bernard Beer,Arnold S. Lippa,Arnold S. Lippa +6 more
TL;DR: Biochemical, electrophysiological, and pharmacological evidence supporting a role for cholinergic dysfunction in age-related memory disturbances is critically reviewed and an attempt has been made to identify pseudoissues, resolve certain controversies, and clarify misconceptions that have occurred in the literature.
Journal ArticleDOI
Global prevalence of dementia: a Delphi consensus study
Cleusa P. Ferri,Martin Prince,Carol Brayne,Henry Brodaty,Laura Fratiglioni,Mary Ganguli,Kathleen S. Hall,Kazuo Hasegawa,Hugh C. Hendrie,Yueqin Huang,Anthony F. Jorm,Colin Mathers,Paulo Rossi Menezes,Elizabeth Rimmer,Marcia Scazufca +14 more
TL;DR: Detailed estimates of dementia prevalence for each world region are believed to constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.
Journal ArticleDOI
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois,Howard Feldman,Howard Feldman,Howard Feldman,Claudia Jacova,Jeffrey L. Cummings,Steven T. DeKosky,Pascale Barberger-Gateau,André Delacourte,Giovanni B. Frisoni,Nick C. Fox,Douglas Galasko,Serge Gauthier,Harald Hampel,Gregory A. Jicha,Kenichi Meguro,John T. O'Brien,Florence Pasquier,Philippe Robert,Martin N. Rossor,Steven Salloway,Marie Sarazin,Leonardo Cruz de Souza,Yaakov Stern,Pieter Jelle Visser,Pieter Jelle Visser,Philip Scheltens +26 more
TL;DR: This paper aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities.
Journal ArticleDOI
Statins and the risk of dementia.
Hershel Jick,Gwen L. Zornberg,Gwen L. Zornberg,Susan S. Jick,Sudha Seshadri,David A. Drachman +5 more
TL;DR: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to nonstatin LLAs.
Related Papers (5)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more